• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
+49 (0) 69 / 606 278 – 0
[email protected]
Contact form
Patent- & Rechtsanwaltskanzlei

Patent- & Rechtsanwaltskanzlei

  • Deutsch

+49 (0) 69 / 606 278 – 0

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
  • xing
  • Email
MENUMENU
  • Services
    • Advice On Protective IP Rights
    • Patent Application /TM Registration
    • Enforcement Of IP Rights
    • Defence Against IP Rights Enforcement
    • Costs
  • Company
    • Fields of Law
      • Patent Law
      • Utility Model Law
      • Employees‘ Inventions
      • Trademark Law
      • Design Law
      • Trademark and Product Piracy
      • Expert Opinions
    • Our Law Firm
      • Dr. Karl-Hermann Meyer-Dulheuer
      • Dr. Tim Meyer-Dulheuer
      • Dr. Klaus Zimmermann
      • Zhichao Ying
      • Dr. Christoph Hölscher
    • Commitment
  • Contact
    • Where To Find Us
    • Write us!
    • Request call back
  • Blog

Intervention of a third party and injunction: BGH decision Pemetrexed II

14. June 2021

In the Pemetrexed II decision, the German Federal Supreme Court (BGH) ruled in the interesting legal area of Intervention of a third party and injunction and, incidentally, overturned the previous decision of the BPatG, which had declared the patent invalid.

Nebenintervention - BGH Vitamin B12

The case Pemetrexed II concerned the European patent (EP 1 313 508) on the use of pemetrexed disodium in combination with vitamin B12 to inhibit the growth of tumours. Patent claim 1 is directed to purpose-bound substance protection for the combination of the two active substances mentioned.

The Federal Patent Court (Bundespatentgericht, BPatG) had initially declared this patent invalid in patent revocation proceedings; the defendant successfully appealed against this. The Federal Supreme Court (BGH) overturned the BPatG’s decision and, in its Pemetrexed II decision, secured the legal validity of the patent for injunction (X ZR 150/18).

Intervention of a third party and injunction patent

Since an application for a preliminary injunction for infringement of the patent in suit was also filed against the intervening party at the Munich District Court, the Federal Court of Justice’s Pemetrexed II judgment resulted in a decision in the interesting legal area of intervening party and injunction patent. A patent in respect of which an injunction is to be issued is called an injunction patent for short.

The Federal Supreme Court ruled that in patent nullity proceedings, intervening on the side of the plaintiff in the appeal instance is not inadmissible because the intervening party is attacking the patent with another revocation action on which the patent court has not yet ruled. This is an important decision of the Federal Court of Justice, because it contradicts another view, which is even represented in the literature (Hall/Nobbe in Benkard, PatG, 11th ed., § 81).

The Federal Court of Justice deliberately contradicted this view and emphasised that a legal interest could not be denied because the intervening party – as in this case – had filed its own nullity action against the patent in suit. This applies at least, the BGH explained, if – as here – the patent court has not yet ruled on the action of the intervening party and the proceedings to which the intervening party declares its intervention are already pending in the appeal instance.

In such a constellation, the intervening party’s own invalidity action does not represent a more efficient legal protection option compared to intervening in the appeal proceedings, the BGH explained.

A brief digression: Intervention

If two parties are involved in Germany in a civil case, third parties still have the possibility to participate in the case. In this case, the third party – the so-called intervening party – joins the case, either on the side of the plaintiff or on the side of the defendant.

Such an intervention has advantages and disadvantages for a third party. The advantage is that the intervening party can participate in the proceedings between the main parties and also comprehensively assert means of attack and defence. However, an intervention can be disadvantageous if the outcome of the proceedings is not satisfactory. This is because, as an intervener, he can no longer object that the legal dispute was inadequately conducted by the respective main party.

The BGH emphasised that in the course of the appeal proceedings an earlier decision on the validity of the patent could be expected. An Intervention of a third party can lead to a faster decision also on the basis of a comprehensive investigation of the facts, the court added.

Reasonable expectation of success

Whether there is a reasonable expectation of success in pursuing a solution is to be determined in each individual case:

  • taking into account the field of expertise at issue,
  • the size of the incentive for the expert,
  • the effort required to pursue a particular approach and the alternatives, if any, to be considered
  • and the alternatives, if any, to be considered, as well as their respective advantages and disadvantages.

Incidentally, this is also in line with the BGH case law according to X ZR 59/17- Fulvestrant. In this case, the Federal Supreme Court had ruled on the suggestion of a solution for an expert. According to this decision, the suggestion depended on the associated expectation of success. The requirements for a reasonable expectation of success cannot be formulated in a generally applicable manner, but must be determined in each individual case – precisely under the aspects also mentioned here regarding a reasonable expectation of success.

Formulation for an active pharmaceutical ingredient for human use

In the development of a formulation for an active pharmaceutical ingredient for human use, however, the BGH had added in the Fulvestrant case that it was not generally decisive whether the person skilled in the art could expect to find a result suitable for a clinical trial.

An appropriate expectation of success in this case could already result from the possibility of verifying the efficacy and tolerability of a formulation in an animal experiment with sufficient predictive value for therapeutic use in humans.

Are you interested in intervening in a (nullity) proceedings?

Our (patent) attorneys have many years of expertise in patent law as well as in the entire field of intellectual property and are authorised to represent you before any court – in Germany and also internationally.
Please do not hesitate to contact us if you are interested.

 

 

Sources:

BGH  Pemetrexed II “Vitamin B12”, X ZR 150/18

Image:

our own design based on MIH83 | pixabay | CCO License and stevepb | pixabay | CCO License

  • share  
  • share 
  • share 
  • tweet 
  • share 

Category iconHealthcare & Lifesciences,  Patent Law Tag iconVitamin B12,  intervening party,  preliminary injunction,  for human use,  Fulvestrant,  BGH case law,  patent nullity proceedings,  injunction patent,  interlocutory proceedings,  human medicinal product,  BGH,  BGH Pemetrexed II,  Vitamin B 12

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

More articles about: Healthcare & Lifesciences

All articles

Blog Menu

  • Design Law
  • Healthcare & Lifesciences
  • International Intellectual Property
  • Licenses
  • News from our law firm
  • Overall
  • Patent Law
  • Product- and Trademark piracy
  • Trademark Law

Recent Posts

  • BPatG: Patent claim of cancer drug on active substance as salt 7. March 2022
  • Grant for European IP Protection: SME Fund 2022 4. March 2022
  • CODE-X vs. Cody’s: Likelihood of confusion in drinks? 25. February 2022
  • EOS lip balm no 3D trademark – appeal before ECJ not admissible 24. February 2022

Fields of Law

  • Patent Law
  • Utility Model Law
  • Employees’ Inventions
  • Trademark Law
  • Design Law
  • Trademark and Product Piracy
  • Expert Opinions
  • Costs

Das könnte Sie auch interessieren:

7. March 2022
BPatG: Patent claim of cancer drug on active substance as salt

BPatG: Patent claim of cancer drug on active substance as salt

4. March 2022
Grant for European IP Protection: SME Fund 2022

Grant for European IP Protection: SME Fund 2022

22. February 2022
PAP is in force: UPC possible in 2022

PAP is in force: UPC possible in 2022

8. February 2022
Germany: Value in dispute and costs in proceedings

Germany: Value in dispute and costs in proceedings

3. February 2022
PCT application – does the principle of joint applicants apply?

PCT application – does the principle of joint applicants apply?

1. February 2022
Proof of patent infringement by whistleblower

Proof of patent infringement by whistleblower

Contact us or request a call back

+49 (0) 69 / 606 278 – 0
[email protected]
Request a call back

Footer

Contact

Torhaus Westhafen
Speicherstrasse 59
D – 60327 Frankfurt am Main
Deutschland
+49 (0) 69 / 606 278 – 0
+49 (0) 69 / 606 278 – 199
[email protected]

Office Hours
Moday – Friday:   08:00-18:00

Fields of Law

  • Patent Law
  • Utility Model Law
  • Employees’ Inventions
  • Trademark Law
  • Design Law
  • Trademark and Product Piracy
  • Expert Opinions
  • Costs

Law Firm

  • Request non-binding call back
  • Company
  • Our Law Firm
  • ISO Certificate
  • Privacy Policy
  • Data handling for clients
  • Imprint

Follow Us

  • Facebook
  • Twitter
  • LinkedIn
  • xing
  • Email

Newsletter Signup

© Patent- & Rechtsanwaltskanzlei Meyer-Dulheuer MD Legal Patentanwälte PartG mbB

Contact Form

 

Give us a call, send us an email or fill out the contact form.

+49 (0) 69 / 606 278 – 0
[email protected]

Kontaktformular

 

Rufen Sie uns an, schicken Sie uns eine Mail oder füllen Sie das Kontaktformular aus.

+49 (0) 69 / 606 278 – 0
[email protected]